荣昌生物制药（烟台）股份有限公司2022年及2023年A股限制性股票激励计划相关权益对应归属期归属结果暨股份上市公告

Core Viewpoint - The announcement details the completion of the stock registration for the 2022 and 2023 A-share restricted stock incentive plans of Rongchang Biopharmaceutical (Yantai) Co., Ltd, including the listing of 767,240 shares on January 26, 2026 [2][19]. Summary by Sections Stock Listing and Incentive Plan - The stock listing type is for equity incentive shares, with a total of 767,240 shares to be listed for circulation on January 26, 2026 [2]. - The company has completed the registration of shares for the third vesting period of Class A rights and the first vesting period of Class B rights under the 2022 A-share restricted stock incentive plan, as well as the first vesting period of the 2023 plan [2][21]. Decision-Making Process - The decision-making process for the 2022 A-share restricted stock incentive plan involved multiple meetings, including the first board meeting on October 16, 2022, where the plan was approved [3][4]. - The plan was publicly announced and underwent a verification process by the supervisory board, which confirmed the legitimacy of the incentive objects [3][4][5]. Shareholder Meetings and Approvals - The company held several shareholder meetings, including the second extraordinary general meeting on December 28, 2022, where the incentive plan was approved [5][13]. - The independent directors provided their opinions supporting the incentive plan during the meetings [6][11]. Stock Vesting Details - For the 2022 A-share restricted stock incentive plan, 128,850 shares of Class A rights were eligible for vesting, with 21 participants, while 497,760 shares of Class B rights were eligible for 112 participants [17]. - For the 2023 A-share restricted stock incentive plan, 234,600 shares were eligible for 18 participants, with some shares not vesting due to funding arrangements [18]. Financial Impact - The newly vested shares represent approximately 0.14% of the total share capital, which is not expected to have a significant impact on the company's recent financial performance [21].